 Geneva, Switzerland, August 12 , 2022 - Addex Therapeutics SIX and Nasdaq: ADXN, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST 15:00 BST 10:00 EDT 07:00 PDT the same day. 